Vascular Liver Disease: From Bench to Bedside
Nov
13
2023
Room 312
-
Hynes Convention Center
11:00
AM
- 12:30 PM EST
Speakers
Description
Abstracts
- BAR501, A SELECTIVE GPBAR1 AGONIST, REDUCES VASCULAR INFLAMMATION AND ATHEROSCLEROSIS IN A MOUSE MODEL OF MASLD
- REDUCE DOSE SAFETY OF DIRECT ORAL ANTICOAGULANTS IN CIRRHOTIC PATIENTS AND PORTAL VEIN THROMBOSIS WITH COEXISTENT SIGNIFICANT THROMBOCYTOPENIA: A MULTI-COUNTRY STUDY
- PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE ARE AT HIGHER RISK OF PROCEDURAL-RELATED BLEEDING
- LIVER LYMPHANGIOGENESIS MITIGATES THE PROGRESSION OF FIBROSIS
- SAFETY OF DOACS IN PATIENTS WITH CHILD-PUGH CLASS C CIRRHOSIS AND ATRIAL FIBRILLATION
- A COMPARATIVE ANALYSIS OF OUTCOMES BETWEEN DIRECT ORAL ANTICOAGULANTS AND LOW-MOLECULAR-WEIGHT HEPARIN OR VITAMIN K ANTAGONISTS IN BUDD-CHIARI SYNDROME: A GLOBAL MULTICENTER PROPENSITY-MATCHED STUDY